Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized optimization study of antipsychotic treatment in schizophrenia
ChiCTR1800014755Phase 4Recruiting
- Sponsor
- Ministry of Science and Technology of the People's Republic of China
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of risperidone, olanzapine, aripiprazole and quetiapine in schizophrenia (4 arms), sponsored by Ministry of Science and Technology of the People's Republic of China. Primary endpoints: PANSS reduction rate and Metabolic and other safety indices. Started Jul 2016; status: recruiting.
02
Drugs
risperidoneolanzapinearipiprazolequetiapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ChiCTR1800014755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014755.